AVOS Life Sciences

Table of Contents - Diabetes

Tables and Figures 5
Disease Etiology 7
Epidemiology and Patient Population Estimates 8
Screening and Diagnosis 8
Theoretical Patient Population 9
Addressable Patient Population 9
Treated Patient Population 9
Patient-Years of Therapy 9
U.S. Anti-diabetes Market Model, 2004-2013 12
Disease and Market Definitions 12
OAD/GLP-1 Market 12
Biguanides and Sulfonylureas 12
PPARγ Agonists 13
DPP-IV Inhibitors 13
Meglitinides 13
β-Glucosidase Inhibitors 13
Fixed-Dose Combinations 13
Insulin Market 13
Forecasting Methodology 14
Market Revenue Forecasts 19
AVOS Physician Panel Results 20
Physician Treatment Patterns for Type 1 Diabetes 20
Physician Treatment Patterns for Type 2 Diabetes 20
Patient Compliance 21
Asymptomatic Nature of Type 2 Diabetes 21
Side-effects 21
Patient Sentiments/Attitudes 21
Patient Demographics 21
Physician Product Selection Criteria 21
HbA1c Reduction Efficacy 21
Side-effect Profile 21
Cardiovascular Risk 21
Weight Gain 22
Hypoglycemia 22
Cost 22
Convenience of Use 22
Other Criteria 22
Physician Product Ratings and Forecasts of Market Trends 22
Market Overview 26
Leading Products 27
Market History 27
Current Market Environment 28
Oral Anti-diabetes Drugs/GLP-1 Analogues 28
Insulin 28
Marketed Product Profiles
Actos (Takeda/Eli Lilly) 29
U.S. Perspective 29
Worldwide Perspective 30
AVOS Physician Panel Discussions 31
Avandia (GlaxoSmithKline) 32
U.S. Perspective 32
Worldwide Perspective 33
AVOS Physician Panel Discussions 33
Januvia (Merck) 35
U.S. Perspective 35
Worldwide Perspective 36
AVOS Physician Panel Discussions 36
Byetta (Amylin Pharmaceuticals/Eli Lilly) 37
U.S. Perspective 37
Worldwide Perspective 38
AVOS Physician Panel Discussions 38
Prandin/NovoNorm (Novo Nordisk) 39
U.S. Perspective 39
Worldwide Perspective 40
AVOS Physician Panel Discussions 40
Exubera (Pfizer) 41
U.S. Perspective 41
Worldwide Perspective 42
AVOS Physician Panel Discussions 42
Lantus (Sanofi-Aventis)/Levemir (Novo Nordisk) 44
U.S. Perspective 44
Worldwide Perspective 45
AVOS Physician Panel Discussions 45
Humalog (Eli Lilly)/NovoLog (Novo Nordisk)/ Apidra (Sanofi-Aventis) 46
U.S. Perspective 47
Worldwide Perspective 47
AVOS Physician Panel Discussions 47
Humulin (Eli Lilly)/Novolin (Novo Nordisk) 49
U.S. Perspective 49
Worldwide Perspective 50
AVOS Physician Panel Discussions 50
Pipeline Product Profiles
Byetta LAR (Amylin Pharmaceuticals/Eli Lilly)/ Liraglutide (Novo Nordisk) 51
U.S. Perspective 51
Worldwide Perspective 52
AVOS Physician Panel Discussions 52
Saxagliptin (BMS)/SYR-322 (Takeda)/Galvus (Novartis) 53
U.S. Perspective 53
Worldwide Perspective 54
AVOS Physician Panel Discussions 54
AIR (Alkermes/Eli Lilly)/AERx (Novo Nordisk)/ Technosphere Insulin (MannKind) and Oral-lyn (Generex Biotechnology) 55
U.S. Perspective 55
Worldwide Perspective 56
AVOS Physician Panel Discussions 56
Drugs in Development 57
R&D Overview 57
Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors 57
GLP-1 Analogues 57
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists 57
Sodium-Dependent Glucose Transporter-2 (SGLT-2) Inhibitors 57
Protein Tyrosine Phosphatase 1b (PTP1b) Inhibitors 57
11-β Hydroxysteroid Dehydrogenase-1 (11 β-HSD-1) Inhibitors 57
Commercial Prospects for Key Drug Classes 57
Products in the Pipeline (listed alphabetically) 60
Phase III (25 agents) 60
Phase II (65 agents) 62
Cover

Production date: October 2007

Model Updated: July 2008

Order

Print Copy - $5,000

Single Site license PDF - $7,000

Global License PDF - $9,995

Contact Information:

If you wish to see sample pages or to learn more about AVOS Therapeutic Market Reports, contact Mike Goodman
919-475-9695
reports@avoslifesciences.com